Results 41 to 50 of about 15,799 (221)
Hepatitis C virus resistance to the new direct-acting antivirals [PDF]
, 2016 Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella +2 more
core +1 more source
Hepatitis C virus NS5A targets the nucleosome assembly protein NAP1L1 to control the innate cellular response [PDF]
, 2017 Hepatitis C virus (HCV) is a single-stranded positive-sense RNA hepatotropic virus. Despite cellular defenses, HCV is able to replicate in hepatocytes and to establish a chronic infection that could lead to severe complications and hepatocellular ...
Cesarec, Mia +5 more
core +1 more source
5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt
Journal of Advanced Research, 2018 Chronic hepatitis C virus (HCV) infection is a main health problem in Egypt causing high rates of mortalities. Egypt has the highest HCV prevalence in the world, with specific HCV subtypes epidemic and circulating extensively in the country.
Radwa R. El-Tahan +2 more
doaj +1 more source
Biomédica: revista del Instituto Nacional de Salud, 2018 Introduction: Hepatitis C virus (HCV) displays high genetic variability, with seven genotypes and numerous subtypes. The determination of the viral type has been essential for the selection and timing of antiviral treatment.
Pierina D’Angelo +7 more
doaj +1 more source
Geographical and chronological origin and evolution of Hepatitis C Virus. [PDF]
, 2011 Hepatitis C Virus (HCV) infection is a major health problem that leads to cirrhosis and hepatocellular carcinoma. World over, more than 270-300 million people are estimated to be infected with the virus.
Achuthsankar S. Nair +2 more
core +2 more sources
Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
Hepatology Research, EarlyView.ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki +10 more
wiley +1 more source
Infection and Drug Resistance, 2022 Thu Kim Nguyen,1,2 Duyet Van Le1 1Clinical Laboratories, National Hospital for Tropical Diseases, Hanoi, Vietnam; 2Infectious Department, Hanoi Medical University, Hanoi, VietnamCorrespondence: Duyet Van Le, Tel +84936647979, Email duyetibt@gmail ...
Nguyen TK, Van Le D
doaj
Hepatitis C virus genotyping based on Core and NS5B regions in Cameroonian patients
Virology Journal, 2019 Background Current HCV treatments are genotype specific although potential pan-genotype treatments have recently been described. Therefore, genotyping is an essential tool for the therapeutic management of HCV infection and a variety of technologies have
Paul Alain Tagnouokam-Ngoupo +7 more
doaj +1 more source
Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking. [PDF]
PLoS ONE, 2016 The NS5B polymerase is one of the most attractive targets for developing new drugs to block Hepatitis C virus (HCV) infection. We describe the discovery of novel potent HCV NS5B polymerase inhibitors by employing a virtual screening (VS) approach, which ...
Yu Wei +10 more
doaj +1 more source
Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications
Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff +2 more
wiley +1 more source